Reverse Split and New Clinical Data, What's Next for Advaxis?
NEW YORK, NY / ACCESSWIRE / April 1, 2019 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive report on Advaxis, Inc. (ADXS), a late-stage biotechnology company focused on the discovery, development, and commercialization of proprietary Lm-based antigen delivery products.
The company's shares are trading with robust volumes as it announces updated data from the Phase 1/2 KEYNOTE-046 study in metastatic, castration-resistant prostate cancer (mCRPC). This trial is being conducted in conjunction with Merck (known as MSD outside the U.S. and Canada) and is evaluating ADXS-PSA, one of Advaxis' Listeria monocytogenes (Lm)-based immunotherapies, alone and in combination with KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 therapy.
Get the highlights of the new clinical data, management's comments and more READ MORE
Copy and paste to your browser may be required to view the report - https://tradersnewssource.com/advaxis/
The Company initiated its first clinical trial using a novel and proprietary approach to cancer immunotherapy that targets hotspot mutations, cancer testis antigens, and oncofetal antigens. The first drug candidate from this program, ADXS-503, is designed to treat all types of non-small cell lung cancer and is now enrolling patients. The end of June 2019 anticipates Safety, tolerability and immune correlative data from this Phase1/2 study.
ADXS is an emerging player in the anti-tumor immunity segment, and 2019 is expected to be a remarkable year for biotech space and oncology/cancer segment will likely continue to dominate the industry.
ADXS pipeline and the potential market for its products in the full report READ MORE
Copy and paste to your browser may be required to view the report - https://tradersnewssource.com/advaxis/
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither TNS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit https://www.tradersnewssource.com.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
CONTACT: editor@tradersnewssource.com
SOURCE: Traders News Source
View source version on accesswire.com:
https://www.accesswire.com/540701/Reverse-Split-and-New-Clinical-Data-Whats-Next-for-Advaxis
